Table 4.

Pathology results from percutaneous core biopsy or FNA performed during the COVID-19 pandemic, and one year prior during the pre-pandemic times

BI-RADS classification	Pandemic (n = 34)	Pre-pandemic (n = 21)
Ductal carcinoma in situ (DCIS)	2 (5.9%)	1 (4.8%)
Invasive ductal carcinoma (IDC)	9 (26.5%)	5 (23.8%)
IDC with axillary lymph node metastasis	3 (8.8%)	0
IDC and DCIS	1 (2.9%)	0
Invasive lobular carcinoma (ILC)	1 (2.9%)	0
Diffuse large B cell lymphoma	0	1 (4.8%)
Various benign pathologies	16 (47.1%)	12 (57.1%)
Atypical benign pathology results	2 (5.9%)	2 (9.5%)